Editas, Church further dispute CRISPR off-target report

In response to a letter published in Nature Methods last month that found a high level of off-target mutations in mice treated with CRISPR/Cas9, executives at Editas Medicine Inc. (NASDAQ:EDIT) along with academic CRISPR expert

Read the full 358 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE